basal cell carcinoma
Oncology · 2005–2023
11decisions
6medicines
2carried consumer input
6individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| sonidegib Treatment of metastatic or locally advanced basal cell carcinoma (BCC) in patients inappropriate for surgery and curative radiotherapy. | Jul 2023 | Noted | none received |
| vismodegib Metastatic or locally advanced basal cell carcinoma that is inappropriate for surgery and inappropriate for curative radiotherapy. | Nov 2017 | Recommended | no section in document |
| sonidegib Treatment of locally advanced basal cell carcinoma (laBCC) or metastatic basal cell carcinoma (mBCC) in patients who are inappropriate for surgery and curative… | Nov 2017 | Recommended with restriction | none received |
| vismodegib Treatment of adult patients with metastatic or locally advanced basal cell carcinoma (BCC) where surgery and radiotherapy are not appropriate. | Mar 2016 | Recommended with restriction | 5 individuals |
| vismodegib Treatment of adult patients with metastatic or locally advanced basal cell carcinoma (BCC) where surgery and radiotherapy are not appropriate. | Nov 2016 | Recommended with restriction | 1 individuals |
| methyl 5-aminolevulinate hydrochloride Treatment of superficial basal cell carcinoma (sBCC) in patients who cannot have surgical excision, cryotherapy, or curettage with diathermy. | Mar 2008 | Recommended | no section in document |
| methyl 5-aminolevulinate hydrochloride treatment of superficial basal cell carcinoma (sBCC) in patients who cannot have surgical excision, cryotherapy, or curettage with diathermy | Jul 2007 | Not recommended | no section in document |
| imiquimod, cream primary treatment of biopsy confirmed superficial basal cell carcinoma where surgery is considered inappropriate based on one or more of the following clinical… | Nov 2005 | Not recommended | no section in document |
| imiquimod Primary treatment of biopsy-confirmed superficial basal cell carcinoma where surgery is considered inappropriate. | Nov 2005 | Not recommended | no section in document |
| methyl aminolevulinate Treatment of patients aged 18 years or older with primary superficial basal cell carcinoma (sBCC) or nodular basal cell carcinoma (nBCC) where surgery is… | Nov 2005 | Not recommended | no section in document |
| methyl aminolevulinate Treatment of patients aged 18 years or older with primary superficial basal cell carcinoma (sBCC) or nodular basal cell carcinoma (nBCC) where surgery is… | 2005 | Not recommended | no section in document |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 5 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.